Updated thoughts on SARS-CoV-2 and coronavirus therapies, fighting and surviving

WENJUAN LI*; GE SONG

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, USA

Key words: SARS-CoV2, Cellular mechanism, Therapies, Antibody, Vaccine

Abstract: From late December 2019 a new human-adapted coronavirus, SARS-CoV-2, was observed and isolated in clustered patients in Wuhan, China. It has been proved to be able to transmit human-to-human and cause pneumonia, leading to about 2% fatality. Its genome characteristics, immune responses and related potential treatments, such as chemical drugs, serum transfusion and vaccines including DNA vaccines, are discussed in this review for a brief summary.

Introduction

In December 2019, several clustered cases of pneumonia (Chan et al., 2020) were reported in Wuhan, Hubei province, China. Shortly later on January 7th, 2020, a novel virus was observed in the throat swab sample from one patient under electronic microscopy. Its characteristics appeared obviously corona-like, thus it was identified as a coronavirus. WHO declared this outbreak a global health emergency, and named it as SARS-CoV-2 subsequently in February. Since several coronaviruses have hit human society previously, among which the most severe ones were SARS-CoV-1 in 2003–2004 and MERS-CoV in 2012, their information and most recent researches have provided us the opportunity to know this new virus better. Here we take a brief view about SARS-CoV-2, its related symptoms, and therapies along with its other family members.

New virus and coronavirus family

SARS-CoV-2’s genome later on was sequenced and determined to belong to betacoronaviruses, whose higher Coronavirus genus belongs to the Coronaviridae family. Members of this family hold one single positive-sense RNA of around 30 kb as their genetic material. SARS-CoV and MERS-CoV are two well-known betacoronaviruses with respectively 27.9 kb and 30.1 kb lengths for their genomes. At the time of writing of this review, the genome of SARS-CoV-2 has been sequenced and uploaded to virological.org, by the research group of Edward C. Holmes and Yongzheng Zhang, et al. Summarized and briefly analyzed in other works (Dong et al., 2020; Paraskevis et al., 2020; Xu et al., 2020), SARS-CoV-2 has a 29,903 bp-long genome, containing 10 genes, with higher homology to SARS-CoV than to MERS-CoV. The amino acid sequence identity of their receptor binding proteins, the Spike protein, is around 76%. More analysis and interpretations by researchers are currently accelerating in order to understand this virus better and to develop better therapies.

Usually, the order Nidovirales RNA genome has a unique gene distribution pattern, with two-thirds of the genome from the 5’ end encoding two large polyproteins, and the rest transcribed into a set of subgenomic mRNAs (Pasternak et al., 2006; Perlman and Netland, 2009)(Fig. 1). The polyproteins are pp1a and pp1ab, including 16 non-structural proteins (nsp1-nsp16) that form the viral replicase-transcriptase complex. Among these 16 proteins, there are two proteases including a papain-like protease (PLpro) and a main protease, 3C-like protease (3CLpro), corresponding to nsp3 and nsp5. For the rest of the genome, SARS-CoV and MERS-CoV respectively transcribe to 12 and 9 subgenomic RNAs encoding the four important structural proteins as spike (S), envelope (E), membrane (M) and nucleocapsid (N), as well as several accessory proteins that interfere with the host immune response and maybe harbor other unclear functions.

When the coronavirus particles enter the hosts (Fig. 2), their envelope spike glycoprotein binds to the cellular receptors and leads to membrane fusion, either directly with the host cell
membrane or with endosome membrane after being engulfed. At this point, the viral RNA genome is released into the cytoplasm and becomes uncoated. Translation of the first two-thirds of genes into two large polyproteins starts. The two proteases PLpro and 3CLpro from nsp3 and nsp5 cleave the two polyproteins and allow them to pack into replicase-transcriptase complexes, which largely amplify the replication and transcription process. Positive-sense RNA genomes are replicated into negative-sense RNAs, then transcribed into subgenomic positive-sense mRNAs, followed by translation into structural proteins including spike, membrane, envelope and nucleocapsid proteins, which are prepared for the packaging and release of new viral particles.

After the spike protein on virus envelope binds to responding host cellular receptors, cellular membrane fusion or endocytosis starts, allowing viral genome to get into cytoplasm. ORF1a and ORF1b are first translated to produce two large polymerase proteins: pp1a, pp1ab. These polymerase proteins are cleaved to form the RNA replicase-transcriptase complex, which serves for the viral genome replication and viral protein transcription. Then the viral mRNAs hire the host cell’s translation machines to produce their own proteins. The resulting structural proteins are ready to wait for the viral genome packed by nucleocapsids to assemble new virus particles. Finally the nascent virions release from the infected cell.

Coronavirus Reservoirs and SARS-CoV-2 Reservoirs, Transmission, Clinical Symptoms and Diagnosis

Most reported coronaviruses exist in wild animals, especially in bats.

After years of investigation, the origin of SARS-CoV (Li et al., 2005; Menachery et al., 2015) as well as the MERS-CoV-like viruses (Drexler et al., 2014) were finally tracked to bats. Since SARS-CoV-2 has not been diagnosed in humans previously and all the first infection cases showed strong correlation with the wholesale seafood market in Wuhan city, SARS-CoV-2 was more commonly considered to be originated from wild animals. Bats are possible origins again in this case, given the fact that virus isolated from patients showed 96% similarity with a bat coronavirus on the whole-genome level (Wu et al., 2020; Zhou et al., 2020). Although there was also evidence showing SARS-CoV-2 may come from snakes (Ji et al., 2020) or pangolin (Wong et al., 2020), further researches on SARS-CoV-2 are still going on. Thus, the discontinuation of zoonotic activities with the animals that are potentially carrying the viruses would be helpful to control the breakout and development of infections.

It has been evident that SARS-CoV-2 is able to transmit from person to person (Riou and Althaus, 2020). It has an incubation period of 1–4 days, and patients develop disease
symptoms within 24 days. A furin-like cleavage site was identified from the SARS-CoV-2 sequence which is absent in SARS-CoV. Cleavage by furin, which is highly expressed in lungs, has been found to be associated with pathogenicity of viruses including other clades of coronaviruses as well as influenza (Coutard et al., 2020). Therefore, inhibitors for the cleavage could be one of the possible therapeutic strategies.

As for the transmission within the human society, studies show the nosocomial transmission is the predominant route of both SARS-CoV and MERS-CoV (Chowell et al., 2015; Hunter et al., 2016), which is possibly due to the close distance and high regional density of suspending viral particles. Nowadays, it has been clearer that SARS-CoV-2 could transmit via an airborne route as well as physical contact.

Although bats carrying the virus showed no symptoms, infected human individuals present illnesses such as coughing, fever and breathing difficulties, some developing fluid in the lungs (Huang et al., 2020), which is a typically severe pneumonia symptom and causes a drop in oxygen levels, followed by organ failure and eventually death. Under chest X-rays, severe patients showed decreased brightness of lungs and large ground-glass opacity. According to the reported infection cases, there is no age or gender bias for SARS-CoV-2. However, among the fatal cases, 74% have been shown to be age-advanced males in weaker health conditions, such as cancer, renal and lung diseases as well as diabetes mellitus.

The earliest clinical diagnosis had mostly relied on Real Time-PCR (RT-PCR) for specific genetic regions in SARS-CoV-2, which could distinguish it from common pneumonia and flu viruses as well as more specific human coronavirus strains like SARS-CoV and MERS-CoV. Two of the four earliest certified products came from BGI, one of which was RT-PCR based. The other diagnostic kits are based on sequencing, another golden standard for detection. RT-PCR and sequencing sometimes would lead to false negative results due to low virus load in infected patients or samples damaged during storage. Later on, when the genomic sequencing was available, the enzyme-linked immunosorbent assay (ELISA) detection kits based on viral proteins were developed. Colloidal gold immunochromatographic signal-amplifying test strips were as well widely used as diagnostic kits, as a result of their user-friendly format, short time required (2~3 hours), stability in various storage conditions and low price. Now several companies are working with full 24-hour shifts to develop and produce enough SARS-CoV-2 diagnostic kits that could give accurate results. To date, hospitals and CDCs have also started setting CT imaging on lung as another diagnostic standard. But there are also some recent reports about individuals that showed positive results by RT-PCR diagnosis kit but have few or almost no symptoms, while capable of transmitting the virus. The difficulty in clinical diagnosis obviously impeded the controlling of virus spreading.

The Immune Responses Induced by Coronavirus and Potential Therapies

Receptors
Coronaviruses use diverse cellular surface proteins as receptors, which profoundly increases the difficulty for prophylaxis. Among three of the most significant examples that caused outbreaks, SARS-CoV uses ACE2 as receptor (Li et al., 2003), MERS-CoV adopts dipeptidyl peptidase 4 as receptor (Raj et al., 2013), while human coronavirus 229E utilizes zinc metalloprotease aminopeptidase N (APN, CD13) as cellular entry access (Delmas et al., 1992; Tresnan and Holmes, 1998; Yeager et al., 1992). There are coronaviruses that infect other animals; for example, mouse hepatitis virus (MHV) takes advantage of murine carinoembryonic antigen-related cell adhesion molecules (CEACAMs), members of the immunoglobulin receptor superfamily.

During the procedure of identifying receptors for these viruses, immunoprecipitation and mass spectrometry always served as detectors. Once several candidates were determined, other assays followed to confirm the hypothesis, such as syncytia formation among cells that express viral fusion proteins and receptors on the cell surface. These approaches have previously been applied to identify the receptors successfully for SARS-CoV-2 (Imai et al., 2005; Li et al., 2003) and MERS-CoV (Raj et al., 2013).

The pathology distribution of SARS-CoV in human body is consistent with ACE2 expression pattern, which is primarily in the bronchus, lung parenchyma and kidney. The specific tissue or organ infection sites remain to be confirmed on both clinical and molecular-biological level, so that the symptoms could be treated with more accurate medicines and therapies. Similarly, once the receptor of SARS-CoV-2 is identified, assuming it is/they are not novel proteins, the already existing antibodies, peptides and small compounds targeting it/them could be useful in the treatment. There were evidences (Lu et al., 2020; Wan et al., 2020; Wrapp et al., 2020) that showed binding affinity of SARS-CoV-2 to hACE2, raising the possibility that the medicines used in SARS treatment against ACE2 would be effective.

SARS-CoV-2 was first discovered in patients’ lower respiratory tract (Huang et al., 2020), which is consistent with the ACE2 expression pattern. ACE2 was reported to especially highly expressed on type 2 alveolar cells. Another possibility would be that free ACE2 or other chemical substances with higher affinities delivered to pulmonary alveoli would compete with host cells that could probably “trick” the virus, similar to the mechanism by which Oseltamivir and Zanamivir work on influenza virus neuraminidase (McNicholl and McNicholl, 2001).

Virus replication and innate immune response
Since the coronavirus has a huge single positive RNA, once the genome was released into the infected cell, there is a high possibility that it would activate the pattern recognition receptor (PRR) signal pathway, especially dsRNA-related pathways, for example, melanoma differentiation-associated protein 5 (MDA5) (Siu et al., 2014) and retinoic acid-inducible gene 1 protein (RIG-I) pathway (Jensen and Thomsen, 2012) in cellular plasma, or endosomal Toll-like receptors (TLRs) TLR7 and TLR8 (de Marcken et al., 2019) if the viral single-strand RNAs were sensed in endosome (Fig. 3a). This will lead to activation of transcription factor nuclear factor-xB (NF-xB) or Interferon regulatory factor 7 (IRF7) followed by production of type I IFNs. Type 1 IFN would work through IFNα/β receptor and downstream
cascades to generate antiviral proteins encoded by IFN-stimulated genes (ISG). NF-κB in turn induces transcription of pro-inflammatory cytokines. These two critical secreted ligands thus trigger the individual’s antiviral innate system to limit viral replication in infected and neighboring cells. This innate immune response activation has been observed and proved in cases of SARS-CoV and MERS-CoV. In a mouse model infected by SARS-CoV, TNFα, IL-6, CXCL10, CCL2, CCL3, and CCL5 were largely enhanced (Chen et al., 2010). However, these two viruses adopt many strategies to avoid being detected by the host cell, for example, replicating in virus-induced double-membrane vesicles that lack PRRs. On the other hand, when the chemokines and cytokines are released without constraint, they would cause organ damage even failure, which is called cytokine storm. In the 2003 SARS epidemic, as well as H5N1 and H7N9 infections, lungs were the major targeted organ.

a) Innate immune response: once the virus unloaded its genome RNA, and related transcribed RNA, they would be detected by pattern recognition receptors (PRRs), as double-stranded RNA (dsRNA) or uncapped mRNA. Retinoic acid-inducible gene I protein (RIG-I) and melanoma differentiation-associated protein 5 (MDA5) are activated by foreign RNA, then they activated MAVS. If the single stranded RNAs are located in endosome, they would be detected by TLR7 or TLR8. The following pathways of MAVS, meaning NF-κB

FIGURE 3. Immune response caused by betacoronavirus in human body.
get activated and translocated to nucleus, as well IRF3 and IRF7 get phosphorylated and translocated to nucleus. They boost the production of type I IFN and pro-inflammatory cytokines. These IFNs and pro-inflammatory cytokines would bind to the cell’s own or other cell’s IFN receptors, activate STAT1/STAT2, and induce IFN-stimulated genes (ISGs). ISGs largely boost an antiviral innate immune response, limiting viral replication and infection on nearby host cells.

b) Humoral immune response: once the antigens from the virus are presented, they would contact millions of BCRs with a wide range of affinities to antigens. If the affinity is higher, the BCR signal would be stronger, thus B cells with specific BCRs would proliferate faster and survive longer, and would more possibly develop into plasma B cells. During this development, the cytokines secreted by T cells help the B cells to proliferate and mature into antibody producing plasma cells. Designed vaccines are assumed and proved to work in most of the cases that would largely boost specific BCRs, normally aiming broadly neutralizing antibodies, to be produced or dominated during the infection, then remain active as memory B cells and ready for upcoming infection. The antibodies work through several ways. 1. Directly neutralizing the antigens, to precipitate the antigen, waiting to be eliminated by macrophages or other physical ways like sneezing. 2. Labeling the antigens and recruiting FcR cell like phagocytes for endocytosis and degradation. 3. The antigens presented by the infected cells would recruit and activate NK cell to attack infected cells for halting virus replication. 4. Followed by complementary system activation, which could either lead to lysis on pathogen itself or infected cells. 5. Complementary proteins as well would recruit NK cells or macrophages and induce inflammatory cells, like neutrophil enrichment and activation.

Soon after coronaviruses enter the host cell, translation of ORF1a 3CLpro and PLpro is necessary for viral polyprotein cleavage. Their differences from host cellular protease makes them ideal targets for drug design, which could be contributed by the conservation of 3CLpro and PLpro among different strains in betacoronavirus and the already known crystal structures. This possibility of inducing broad-spectrum antiviral activity had been explored by Rolf Hilgenfeld’s group (Hilgenfeld, 2014), who found that SG85 showed good effect on betacoronavirus clade c Bt-CoV-HKU4 and clade d Bt-CoV-HKU9, but not on alphacoronavirus Bt-CoV HKU8. No further research is coming up to a broad-spectrum Main protease (Mpro) and papain-like protease (PLpro) largely due to sharply declined funding during 2005 to 2006.

Other chemicals, such as 6-mercaptopurine and 6-thioguanine, could inhibit both SARS-CoV and MERS-CoV in vitro (Cheng et al., 2015). However, the species difference and in vivo tests always drew a big gap from screening work to clinical usage. There are teams working on screening current commercial medicines for targeting SARS-CoV-2 Mpro (Liu and Wang, 2020), trying to discover the fastest treatment available, even medicines that would be used off-label in this first early phase.

Remdesivir, which was intentionally designed and applied in Ebola treatment, is a novel nucleotide analog prodrug, and has already largely reduced severity of the first SARS-CoV-2 patient in USA on the second day after receiving it (Holshue et al., 2020). However, this was a compassionate usage based on the worsening clinical status of the patient. Safety and efficacy of remdesivir for treatment of patients with SARS-CoV-2 infection needs to be more closely examined and monitored. As Reuters recently reported, a cocktail of flu and HIV drugs, ritonavir and high doses of Oseltamivir, used by Thai doctors largely reduced the load of SARS-CoV-2 virus to non-detectable level in several severe cases. The underlying mechanisms remain to be further investigated. Darunavir (prezista), used in HIV/AIDS, was as well considered in this epidemic by its antiretroviral ability (Leonis et al., 2012). Arbidol, which was used in flu treatment, has also been applied in SARS-CoV-2 infected patients.

Symptoms in respiration system caused by SARS-CoV-2 are similar to those caused by SARS, H5N1 and H4N9, but with lower fatality rate. Therefore, the treatments could possibly refer to the ones used in H7N9, which is serum filtering (Hu et al., 2013), as a supporting method to win the time for adapted immune system to start functioning in patients’ body. Nowadays, there have been case reports about virus carriers that showed no symptoms described above.

### Humoral immune response

Besides chemical drugs described above, most of the treatments in the first cured cases are supportive methods and symptom management, like acetaminophen and ibuprofen for antipyretic therapy, guaifenesin for easier coughing, saline for prevention of dehydration, and oxygen supplementation for maintaining oxygen saturation level.

Application of specific antibodies against the viruses is always considered as a better specialized therapy. Antibodies generated in individuals can achieve protection either by neutralizing viruses that entered the body, which could be eliminated by innate killer cells and complementary system, or by interrupting virus release, such as the anti-neuraminidase antibodies (Doyle et al., 2013; Karunarathna et al., 2019). Antibodies show high specificities and affinities, thus could stimulate the participation of individual immune responses avidly (Fig. 3b). Studies have clearly illustrated how antibodies from SARS survivors could block attachment of SARS-CoV to the host cell receptor and anti-SARS-CoV S antibody could further trigger fusogenic conformational changes by mimicking the binding interaction (Walls et al., 2019). Serum transfusion protection could be a feasible and promising therapeutic strategy before further studies come up. Antibodies that can bind to invading virus particles were assumed to exist in plasma from survivors, secreted by B cells. Although no high technology is required for drawing the blood or filtering the plasma, the scale of donors and willingness of patients as acceptors, as well as the inflammation-related chemokines and cytokines in serum, are problems that need to be solved. B cells secreting the efficient antibodies could
be sorted out for monoclonal antibody production, thus could better help with the patients or potential patients.

Vaccine is another way to elicit humoral responses leading to high-affinity antibodies. However, not enough effort was made on the drug and vaccine development after SARS abated, and the vaccines for SARS-CoV did not achieve good effects as expected (Roper and Rehm, 2009). Since the majority of coronaviruses cause respiratory system inflammation, broadly neutralizing or targeting antibodies to conserved region of the viruses should be taken into consideration. Yet it is reasonable that the industry did not keep investing on development of SARS-CoV vaccines, since clinical trials often take years, and the virus had probably faded away from human society during this time period.

The concept of broadly neutralizing antibodies was raised and developed with considerable academic achievements in viruses such as HIV (Dubrovskaya et al., 2019; Gorman et al., 2019; Kong et al., 2019; Pinto et al., 2019; Wise et al., 2020) and influenza (Ellebedy et al., 2014; Kadam et al., 2017; Raymond et al., 2018; Tharakaraman et al., 2014, 2015; Xiong et al., 2015). The recent work by McLellan lab (Wrapp et al., 2020) revealed high resolution cryo-EM structure of SARS-CoV-2 spike protein in 3.5 Å-resolution and showed no cross-binding to the already existing SARS mAbs that target the Receptor Binding Domain (RBD). Vaccines aiming at cross-strain activities would be more achievable compared to RBD binding. The stem part of the spike protein could be taken into consideration for vaccine design to elicit broadly neutralizing antibodies (Fig. 3b).

DNA vaccines are a much faster way when confronting an epidemic outbreak. Genetically engineered DNA is injected into individuals and incorporated into the host cell genome, thus can use host cells to produce antigens and continuously induce immune responses, including antibodies (Kutzler and Weiner, 2008) (Fig. 4). DNA vaccine strategies share the advantages of good biocompatibility of plasmid DNA, cost-efficient production, long shelf life, and wider range of immunoglobulin responses. DNA vaccines would also be recommended since normal protein vaccines need at least several months for manufacturing and scaling up. However, due to their targeting efficiency and safety, they are not yet popular, but its era is coming (Hobernik and Bros, 2018).

The codon or immunogenicity optimized antigen DNA was designed and assembled with plasmid carrying necessary transcriptional elements. The plasmids mostly are delivered to the skin, subcutaneous or muscle. The mixed vaccine formulation and adjuvants would help human body response to the vaccine. The plasmids could enter myocytes or keratinocytes, in which the antigen could be expressed and presented on MHC I, released extracellularly, or endocytosed by the dead host cells and presented by APCs. Plasmids could as well enter directly into APC. Then the antigen-loaded APCs would drain to the second lymph node, where CD8 T cells, CD4 T cells and B cells would be activated.

There are DNA vaccines for MERS-CoV (Modjarrad et al., 2019; Yoon and Kim, 2019; Zumla et al., 2019). Till Sep. 2019, one of them had been on clinical trial phase 1. Because the common carriers of MERS-CoV are dromedary camels, a vaccine used on camels was developed as well (Haagmans et al., 2016). Vaccines for bats against coronaviruses are impossible, therefore, the easiest and most reasonable way to avoid exposure to unknown viruses.

![FIGURE 4. Vaccines strategies illustration. DNA vaccine procedure.](image-url)
would be keeping a distance from the wild animals and develop vaccines on human. This vaccine was developed by Moderna, who also responded quickly in the SARS-CoV-2 event, by using mRNA converted from viral sequences. These mRNAs were injected into host individuals and started to produce a viral protein that could potentially trigger humoral response in DNA vaccine receivers.

Outlook

The effort of seeking more efficient, specific targeting therapies for the coronavirus is necessary, not only for the current outbreak of SARS-CoV-2, but also for the continuing coronavirus infections coming up. SARS-CoV in years 2002 to 2003 did not alert human population, MERS-CoV remains circulating in camels, longer observation and further research on the SARS-CoV-2 still need close attention.

There are several cases of individuals who are carrying SARS-CoV-2 but do not show symptoms, which means the hosts would spread the virus unconsciously. Thus best- and worst-case scenarios should be prepared for. If the coronaviruses stay endemic, which means it circulates continuously in a community, then this bomb could explode anytime or regularly, like influenza virus. More efficient broadly cross-strain drugs or vaccines against coronaviruses should be carrying on.

The huge effort of controlling this epidemic, from every aspect (governments, organizations, researchers, all the residents), especially the health-care workers, some of whom even sacrificed their precious lives, should be cherished and deeply honored. Every individual should not forget the huge price paid for disturbing the balance on this planet. This review only briefly summarized the fast-growing knowledge about SARS-CoV-2, lots of important information is still being contributed by many research groups all over the world, and would hopefully help us successfully fight this virus in the near future.

Funding Statement: The authors received no specific funding for this study.

Conflicts of Interest: The authors declare that they have no conflicts of interest to report regarding the present study.

References

Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, Xing F, Liu J, Yip CCY, Poon RWS, Tsui HW, Lo SKF, Chan KH, Poon VKM, Chan WM, Ip JD, Cai JP, Cheng VCC, Chen H, Hui CKM, Yuen KY (2020). A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395: 514–523. DOI 10.1016/S0140-6736(20)30154-9.

Chen J, Lau YF, Lamirande EW, Paddock CD, Barilett JH, Zaki SR, Subbarao K (2010). Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. Journal of Virology 84: 1289–1301. DOI 10.1128/JVI.01281-09.

Cheng KW, Cheng SC, Chen WY, Lin MH, Chuang SJ, Cheng IH, Sun CY, Chou CY (2015). Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. Antiviral Research 115: 9–16. DOI 10.1016/j.antiviral.2014.12.011.

Chowell G, Abdurizak F, Lee S, Lee J, Jung E, Nishiura H, Viboud C (2015). Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study. BMC Medicine 13: 210. DOI 10.1186/s12916-015-0450-0.

Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E (2020). The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Research 176: 104742. DOI 10.1016/j.antiviral.2020.104742.

de Marcken M, Dhalwal K, Danielsen AC, Gauteron AS, Dominguez-Villar M (2019). TLR7 and TLR8 activate distinct pathways in monocytes during RNA virus infection. Science Signaling 12: eaw1347. DOI 10.1126/scisignal.aaw1347.

Delmas B, Gelfi J, L’Haridon R, Vogel S, Norén H, Laude H (1992). Aminopeptidase N is a major receptor for the enteropathogenic coronavirus TGEV. Nature 357: 417–420. DOI 10.1038/357417a0.

Dong N, Yang X, Ye L, Chen K, Chan EWC, Yang M, Chen S (2020). Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China. bioRxiv: 2020.01.20.913368.

Dreder JF, Corman VM, Drosten C (2014). Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS. Antiviral Research 101: 45–56. DOI 10.1016/j.antiviral.2013.10.013.

Dubrovskaya V, Tran K, Oзоровski G, Guenaga J, Wilson R, Bale S, Cottrell CA, Turner HL, Seabright G, O’Dell S, Torres JL, Yang L, Feng Y, Leaman DP, Vazquez Bernat N, Liban T, Louder M, McKee K, Bailer RT, Movsesyan A, Doria-Rose NA, Pancera M, Karlsson Hedestam GB, Zwick MB, Crispin M, Mascola JR, Ward AB, Wyatt RT (2019). Vaccination with glycan-modified HIV NFl envelope trimer-liposomes elicits broadly neutralizing antibodies to multiple sites of vulnerability. Immunity 51: 915–929.e7. DOI 10.1016/j.immuni.2019.10.008.

Ellebedy AH, Krammer F, Li GM, Miller MS, Chiu C, Wrammert J, Chang CY, Davis CW, McCausland M, Elbein R, Edupuganti S, Spearman P, Andrews SF, Wilson PC, Garcia-Sastre A, Mulligan MJ, Mehta AK, Palese P, Ahmed R (2014). SIVmac239 reveals functional similarity of SIV and HIV glycan shields. Immunity 51: 724–734.e4. DOI 10.1016/j.immuni.2019.09.007.
Haagmans BL, van den Brand JM, Raj VS, Volz A, Wohlesein P, Smits SL, Schipper D, Bestebroer TM, Okba N, Fux R, Bensaïd A, Solanes Foz D, Kuiken T, Baumgartner W, Segales J, Sutter G, Osterhaus AD (2016). An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science 351: 77–81. DOI 10.1126/science.aad2128.

Hilgenfeld R (2014). From SARS to MERS: crystallographic studies on coronavirus proteases enable antiviral drug design. FEBS Journal 281: 4085–4096. DOI 10.1111/febs.12936.

Hobernik D, Bros M (2018). DNA vaccines—how far from clinical use? International Journal of Molecular Sciences 19: 3605. DOI 10.3390/ijms19113605.

Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson T, Tural A, Díaz G, Cohn A, Fox L, Patel A, Gerber SL, Kim L, Tong S, Lu X, Lindstrom S, Pallansch MA, Weldon WC, Biggs HM, Uyeki TM, Pillai SK (2020). First case of 2019 novel coronavirus in the United States. New England Journal of Medicine 382: 929–936. DOI 10.1056/NEJMa2001191.

Hu Y, Lu S, Song Z, Wang W, Hao P, Li J, Zhang X, Yen HL, Shi B, Li T, Guan W, Xu L, Liu Y, Wang S, Zhang X, Tian D, Zhu Z, He J, Huang K, Chen H, Zheng L, Li X, Ping J, Kang B, Xi X, Zha L, Li Y, Zhang Z, Peiris M, Yuan Z (2013). Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 381: 2273–2279. DOI 10.1016/S0140-6736(13)61125-3.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Tu Y, Xie J, Wei Y, Wu W, Xie Y, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang J, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497–506. DOI 10.1016/S0140-6736(20)30183-5.

Huntner JC, Nguyen D, Aden B, Al Bandar Z, Al Daheri W, Abu Elkheir K, Khudair A, Al Mulla M, El Saleh F, Imam-baccus H, Al Kaabi N, Sheikh FA, Sasse J, Turner A, Abdel Wareth L, Weber S, Al Ameri A, Abu Amer W, AlAmi NN, Bunga S, Haynes LM, Crackower MA, Fukamizu A, Hui D, Lanzavecchia A, Marasco WA, Shi ZL, Baric RS, Wisen C, Bloom JD, Carragher B, Potter CS, Shapiro L, Weeks RW, Overbaugh J, Kutzler MA, Weiner DB (2008). DNA vaccines: ready for prime time? Nature Reviews Genetics 9: 767–788. DOI 10.1038/nrg2342.

Leonis G, Czyżnikowska Z, Megariotis G, Reis H, Papadopoulos MG (2012). Computational studies of Darunavir into HIV-1 protease and DMPC bilayer: necessary conditions for effective binding and the role of the flaps. Journal of Chemical Information and Modeling 52: 1542–1558. DOI 10.1021/ci300146a.

Li W, Moore MJ, Vasilev A, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzzati K, Greenough TC, Choe H, Farzan M (2003). Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426: 450–454. DOI 10.1038/nature02145.

Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, Wang H, Cramer G, Hu Z, Zhang H, Zhang J, McEachern J, Field H, Dazak P, Eaton BT, Zhang S, Wang LF (2005). Bats are natural reservoirs of SARS-like coronaviruses. Science 310: 676–679. DOI 10.1126/science.1118391.

Liu X, Wang JX (2020). Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines. bioRxiv: 2020.01.29.924100.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395: 565–574. DOI 10.1016/S0140-6736(20)30251-8.

McNicholl IR, McNicholl J (2001). Neuraminidase inhibitors: zanamivir and oseltamivir. Annals of Pharmacotherapy 35: 57–70. DOI 10.1345/aph.10118.

Menacherry VD, Yount BL Jr, Debink K, Agnihotham S, Gralinski LE, Plante JA, Graham RL, Scohey M, Ge XY, Donaldson EF, Randell SH, Lanzavecchia A, Marasco WA, Shi ZL, Baric RS (2015). A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nature Medicine 21: 1508–1513. DOI 10.1038/nm.3985.

Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, Reuscher EL, Robb ML, Racine T, Oh MD, Lamarre C, Zaidi FI, Boyer J, Kudchodkar SB, Jeong M, Darden JM, Park YK, Scott PT, Remigio C, Parikh AP, Wise MC, Patel A, Duperret EK, Kim KY, Choi H, White
